Señales en vivo de 4536.T | Maximiza tus Ganancias con Getagraph.com

Live Chart Being Loaded With Signals

Commentary (26 abr 2024 @ 02:15):

Stats
Volumen de hoy	2.72M
Volumen promedio	1.51M
Capitalización de mercado	549.90B
EPS	¥0 ( 2024-02-07 )
Próxima fecha de ganancias	( ¥13.64 ) 2024-05-08
Last Dividend	¥16.00 ( 2023-03-30 )
Next Dividend	¥0 ( N/A )
P/E	20.28
ATR14	¥0.772 (0.05%)

Volumen Correlación

Largo: 0.33 (neutral)

Corto: 0.33 (neutral)

Signal:(62.647) Neutral

Santen Pharmaceutical Correlación

10 Correlaciones Más Positivas

10 Correlaciones Más Negativas

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Santen Pharmaceutical Correlación - Moneda/Commodity

0.66
( moderate )

0.54
( weak )

0.17
( neutral )

0.48
( neutral )

-0.81
( strong negative )

-0.12
( neutral )

Santen Pharmaceutical Finanzas

Annual	2022
Ingresos:	¥279.04B
Beneficio Bruto:	¥166.09B (59.52 %)
EPS:	¥-38.58

FY	2022
Ingresos:	¥279.04B
Beneficio Bruto:	¥166.09B (59.52 %)
EPS:	¥-38.58

FY	2022
Ingresos:	¥266.26B
Beneficio Bruto:	¥156.59B (58.81 %)
EPS:	¥68.07

FY	2021
Ingresos:	¥249.61B
Beneficio Bruto:	¥151.38B (60.65 %)
EPS:	¥17.09

Financial Reports:

No articles found.

Santen Pharmaceutical Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
¥16.00 (N/A)	¥0 (N/A)	¥16.00 (N/A)	¥0 (N/A)	¥0 (N/A)	¥0 (N/A)	¥0 (N/A)	¥0 (N/A)	¥0 (N/A)	¥0 (N/A)

Santen Pharmaceutical Dividend Information - Ex Dividend Knight

Dividend Sustainability Score: 10.00 - good (100.00%) | Divividend Growth Potential Score: 4.72 - Stable (5.57%)

Very Unsafe

High risk of being cut

Unsafe

Heightened risk of being cut

Borderline

Moderate risk of being cut

Safe

Unlikely to be cut

Very Safe

Very unlikely to be cut

Information

First Dividend	¥2.00	2001-03-27
Last Dividend	¥16.00	2023-03-30
Next Dividend	¥0	N/A
Payout Date	0000-00-00
Next Payout Date	N/A
# dividends	46	--
Total Paid Out	¥423.00	--
Avg. Dividend % Per Year	0.00%	--
Score	3.84	--
Div. Sustainability Score	10.00
Div.Growth Potential Score	4.72
Div. Directional Score	7.93	--

Next Divdend (Est)
(2024-07-03)

¥0 Estimate 1.26 %

Dividend Stability

0.10 Bad

Dividend Score

3.84

Pay Frequency

Semi-Annually

Yearly Payout

Year	Amount	Yield

Dividend Commentary

The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In summary, the company provides a promising overall dividend outlook, balancing both sustainability and growth potential.

Top 10 dividend Companies for JPX

Symbol	Title	Last dividend	Frequency	Yearly Dividend
8570.T	Ex Dividend Knight	2023-08-30	Semi-Annually	0.00%
7905.T	Ex Dividend Knight	2023-09-28	Semi-Annually	0.00%
7059.T	Ex Dividend Junior	2023-09-28	Semi-Annually	0.00%
6370.T	Ex Dividend Knight	2023-09-28	Semi-Annually	0.00%
5288.T	Ex Dividend Knight	2023-09-28	Semi-Annually	0.00%
4346.T	Ex Dividend Junior	2023-09-28	Annually	0.00%
3513.T	Ex Dividend Knight	2023-09-28	Semi-Annually	0.00%
2742.T	Ex Dividend Knight	2024-02-28	Semi-Annually	0.00%
9632.T	Ex Dividend Knight	2024-01-30	Semi-Annually	0.00%
8168.T	Ex Dividend Junior	2024-02-28	Semi-Annually	0.00%

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	0.0918	1.500	8.16	10.00	[0 - 0.5]
returnOnAssetsTTM	0.0648	1.200	7.84	9.41	[0 - 0.3]
returnOnEquityTTM	0.0924	1.500	-0.0848	-0.127	[0.1 - 1]
payoutRatioTTM	0.429	-1.000	5.71	-5.71	[0 - 1]
currentRatioTTM	2.46	0.800	2.72	2.17	[1 - 3]
quickRatioTTM	1.841	0.800	3.88	3.10	[0.8 - 2.5]
cashRatioTTM	0.897	1.500	6.13	9.19	[0.2 - 2]
debtRatioTTM	0.0786	-1.500	8.69	-10.00	[0 - 0.6]
interestCoverageTTM	20.13	1.000	3.66	3.66	[3 - 30]
operatingCashFlowPerShareTTM	192.60	2.00	10.00	10.00	[0 - 30]
freeCashFlowPerShareTTM	162.21	2.00	10.00	10.00	[0 - 20]
debtEquityRatioTTM	0.113	-1.500	9.55	-10.00	[0 - 2.5]
grossProfitMarginTTM	0.606	1.000	3.24	3.24	[0.2 - 0.8]
operatingProfitMarginTTM	0.143	1.000	9.14	9.14	[0.1 - 0.6]
cashFlowToDebtRatioTTM	2.03	1.000	10.00	10.00	[0.2 - 2]
assetTurnoverTTM	0.706	0.800	8.63	6.90	[0.5 - 2]
Total Score				11.14

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	19.29	1.000	8.15	0	[1 - 100]
returnOnEquityTTM	0.0924	2.50	-0.0545	-0.127	[0.1 - 1.5]
freeCashFlowPerShareTTM	162.21	2.00	10.00	10.00	[0 - 30]
dividendYielPercentageTTM	2.18	1.500	10.00	0	[0 - 0.4]
operatingCashFlowPerShareTTM	192.60	2.00	10.00	10.00	[0 - 30]
payoutRatioTTM	0.429	1.500	5.71	-5.71	[0 - 1]
pegRatioTTM	-0.123	1.500	-4.15	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	0.225	1.000	6.86	0	[0.1 - 0.5]
Total Score				4.72

Santen Pharmaceutical

Santen Pharmaceutical Co., Ltd. researches and develops, manufactures, and markets pharmaceuticals and medical devices in Japan and internationally. It offers various pharmaceutical products to treat glaucoma and ocular hypertension, such as DE-111, which is in Phase III clinical trial; DE-117 in Japan; DE-126 that is in Phase IIb clinical trial; DE-128 in Europe, as well as is in Phase II/III clinical trial in the United States; and DE-130A that is in Phase III clinical trial. In addition, the company provides DE-114A to treat allergic conjunctivitis; DE-076C for the treatment of vernal keratoconjunctivitis; and DE-109, which is in Phase III clinical trial to treat uveitis. Further, it offers DE-127 to treat myopia, which is in Phase II/III clinical trial in Japan, as well as is in Phase III in Asia; DE-089C, which has completed Phase III clinical trials for the treatment of dry eye; and STN1013400, which is in Phase I clinical trials for the treatment of myopia. Additionally, the company offers over-the-counter pharmaceutical products. The company was formerly known as Santendo Pharmaceutical Co., Ltd. and changed its name to Santen Pharmaceutical Co., Ltd. in 1958. Santen Pharmaceutical Co., Ltd. was founded in 1890 and is headquartered in Osaka, Japan.